Osinib Tablet 80 mg contains Osimertinib, a targeted tyrosine kinase inhibitor (TKI) used in the treatment of certain types of non-small cell lung cancer (NSCLC). Osimertinib works by selectively inhibiting epidermal growth factor receptor (EGFR) mutations, including the T790M mutation, which is associated with resistance to earlier-generation EGFR inhibitors. By blocking abnormal EGFR signaling, Osimertinib prevents cancer cell growth and proliferation, helping to slow disease progression and improve patient outcomes.

This 80 mg oral tablet is designed for systemic absorption, allowing the medication to reach cancer cells throughout the body, including in the lungs and central nervous system. Osinib is particularly effective for patients with metastatic or advanced NSCLC who have specific EGFR mutations confirmed through molecular testing.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Osinib Tablet 80 mg is indicated for:

• EGFR T790M-positive NSCLC: Patients with advanced or metastatic NSCLC who have progressed on prior EGFR-TKI therapy.

• First-line treatment of EGFR mutation-positive NSCLC: Patients with metastatic NSCLC harboring EGFR exon 19 deletions or exon 21 L858R mutations.

• Brain metastases: Effective in patients with EGFR-mutated NSCLC with central nervous system involvement.

Treatment should only be initiated in patients with confirmed EGFR mutations to ensure efficacy.

Key Benefits

• Targeted therapy: Specifically inhibits mutant EGFR, reducing damage to normal cells.

• Effective against resistant mutations: Targets T790M mutation, which causes resistance to earlier EGFR inhibitors.

• Oral administration: Convenient once-daily dosing improves patient compliance.

• Crosses the blood-brain barrier: Offers control over CNS metastases.

• Improves progression-free survival: Clinical studies demonstrate prolonged disease control compared to chemotherapy in eligible patients.

Osinib provides a personalized treatment approach for patients with EGFR-mutated NSCLC, helping to improve quality of life and clinical outcomes.

Dosage and Administration

• Adults: The recommended dose is 80 mg orally once daily, with or without food.

• Swallow the tablet whole, do not crush or chew.

• Take the tablet at the same time each day to maintain consistent blood levels.

• Dose modifications may be required in case of severe adverse effects or drug interactions.

• Treatment is continued until disease progression or unacceptable toxicity occurs.

Regular monitoring, including cardiac function, liver function, and ECGs, is recommended during therapy.

Precautions

• Use with caution in patients with pre-existing heart disease, interstitial lung disease, or liver impairment.

• Inform your physician about all medications and supplements, as Osimertinib may interact with drugs that affect CYP3A4 enzyme activity.

• Pregnancy and breastfeeding are contraindications; effective contraception is advised during and after treatment.

• Patients should report symptoms such as shortness of breath, chest pain, cough, or severe diarrhea promptly.

Possible Side Effects

Common side effects of Osinib include:

• Diarrhea, nausea, or vomiting

• Skin rash or dry skin

• Fatigue

• Loss of appetite

Serious but less frequent adverse effects may include:

• Interstitial lung disease or pneumonitis

• QT interval prolongation leading to arrhythmias

• Severe cardiac events

Close medical supervision is necessary to manage side effects and adjust therapy as needed.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Storage Instructions

• Store at 20–25°C in a cool, dry place.

• Protect from moisture and direct sunlight.

• Keep the tablets in the original packaging until use.

• Keep out of reach of children.

• Do not use after the expiration date printed on the packaging.

Osinib Tablet 80 mg (Osimertinib) is a targeted, effective therapy for patients with EGFR mutation-positive NSCLC, offering improved disease control, better tolerability, and a personalized approach to lung cancer treatment.